By Drug Target Review2025-11-27T08:30:08
A new mRNA therapy that prompts the body to produce bacteria-killing ‘peptibodies’ has shown early success in preclinical models, offering a potential new tool in the fight against antibiotic-resistant pneumonia.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2024-02-01T11:52:50
Sponsored by Leica Microsystems
2026-03-25T15:00:00 2026-03-25T16:00:00
Sponsored by Yokogawa
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2023-02-07T15:25:20
Sponsored by Bio-Techne
2025-04-02T14:00:00
Sponsored by Eurofins Discovery
Site powered by Webvision Cloud